Each row is a drug, each column a cancer subtype. Cells show the strongest known association for that drug in that cancer: approved clinical trial or blank. The repositionable flag means the drug appears as a synthetic-lethal repositioning candidate in cansar; it’s gene-level, not cancer-level.
| Drug | Target | Relationship | GBM | LUAD | SCLC | LUSC | OAC | OSCC | PDAC | Reposition | #cancers |
|---|---|---|---|---|---|---|---|---|---|---|---|
| aldesleukin, antibody therapy, fluorouracil, gemcitabine hydrochloride, irinotecan hydrochloride, laboratory biomarker analysis, leucovorin calcium, oxaliplatin, paclitaxel albumin-stabilized nanoparticle formulation, sargramostim | IL2RB | Direct | 1 | ||||||||
| aldesleukin, autologous tumor cell vaccine, filgrastim, sargramostim, therapeutic autologous lymphocytes, carmustine, cisplatin, cyclophosphamide, paclitaxel, autologous bone marrow transplantation, conventional surgery, peripheral blood stem cell transplantation | IL2RB | Direct | 1 | ||||||||
| aldesleukin, autologous tumor cell vaccine, muromonab-cd3, sargramostim, therapeutic autologous lymphocytes, surgical procedure, radiation therapy | IL2RB | Direct | 1 | ||||||||
| aldesleukin, biopsy, biospecimen collection, computed tomography, cyclophosphamide, excisional biopsy, fludarabine, magnetic resonance imaging, standard treatment, therapeutic tumor infiltrating lymphocytes | IL2RB | Direct | 1 | ||||||||
| aldesleukin, muromonab-cd3, therapeutic tumor infiltrating lymphocytes, conventional surgery | IL2RB | Direct | 1 | ||||||||
| aldesleukin, therapeutic autologous lymphocytes, adjuvant therapy, conventional surgery | IL2RB | Direct | 1 | ||||||||
| aldesleukin, therapeutic autologous lymphocytes, zoledronic acid | IL2RB | Direct | 1 | ||||||||
| au-007, aldesleukin, avelumab | IL2RB | Direct | 1 | ||||||||
| cyclophosphamide, fludarabine, aldesleukin, anti-hcd70 car transduced pbl | IL2RB | Direct | 1 | ||||||||
| e7 tcr cells, aldesleukin, fludarabine, cyclophosphamide | IL2RB | Direct | 1 | ||||||||
| epidermal growth factor receptor(egfrv)iii chimeric antigen receptor (car) transduced pbl, aldesleukin, fludarabine, cyclophosphamide | IL2RB | Direct | 1 | ||||||||
| kras tcr-transduced pbl, aldesleukin, fludarabine, cyclophosphamide | IL2RB | Direct | 1 | ||||||||
| pep-3-klh conjugate vaccine, daclizumab, temozolomide, placebo, pep-3-klh | IL2RB | Direct | 1 | ||||||||
| rna-loaded dendritic cell vaccine, basiliximab | IL2RB | Direct | 1 | ||||||||
| therapeutic allogeneic lymphocytes, aldesleukin, laboratory biomarker analysis, positron emission tomography | IL2RB | Direct | 1 | ||||||||
| unpulsed dcs, td, human cmv pp65-lamp mrna-pulsed autologous dcs, 111in-labeled dcs, temozolomide, saline, basiliximab | IL2RB | Direct | 1 | ||||||||
| young til, aldesleukin, cyclophosphamide, fludarabine, pembrolizumab (keytruda) | IL2RB | Direct | 1 | ||||||||
| adagrasib | KRAS | SSL via KRAS | yes | 2 | |||||||
| sotorasib | KRAS | SSL via KRAS | yes | 2 | |||||||
| gabapentin, sulfasalazine, memantine, temozolomide, radiotherapy | NFKB2 | SSL via NFKB2 | 1 | ||||||||
| sulfasalazine | NFKB2 | SSL via NFKB2 | 1 | ||||||||
| ataluren | RPL22 | SSL via RPL22 | yes | 0 |